399
Participants
Start Date
September 30, 2007
Primary Completion Date
February 28, 2009
Study Completion Date
February 28, 2009
Placebo
Daily oral dose of two equal intakes, morning and evening, of Placebo in a double-blinded way for the 12-week Treatment Period
Brivaracetam
Daily oral dose of two equal intakes, morning and evening, of Brivaracetam 20 mg /day in a double-blinded way for the 12-week Treatment Period
Brivaracetam
Daily oral dose of two equal intakes, morning and evening, of Brivaracetam 50 mg /day in a double-blinded way for the 12-week Treatment Period.
Brivaracetam
Daily oral dose of two equal intakes, morning and evening, of Brivaracetam 100 mg /day in a double-blinded way for the 12-week Treatment Period.
13, Ghent
19, La Louvière
12, Liège
10, Sankt Vith
44, Kuopio
41, Oulu
42, Seinäjoki
43, Tampere
60, Angers
56, Béthune
62, Bron
57, Dijon
53, Lille
52, Montpellier
64, Nancy
54, Paris
51, Rennes
61, Roanne
55, Strasbourg
76, Bad Berka
73, Berlin
79, Bernau
78, Bielefeld
74, Freiburg im Breisgau
75, Kehl-Kork
77, Mainz
70, München
72, Radeberg
71, Ulm
94, Budapest
90, Debrecen
92, Pécs
256, Bangalore
257, Bangalore
253, Hyderabad
258, Jaipur
255, Kolkata
250, Lucknow
259, Mumbai
270, Pune
251, Pune Maharashtra
104, Bologna
105, Foggia
101, Perugia
103, Roma
107, Roma
124, Breda
125, The Hague
122, Zwolle
142, Bialystok
143, Gdansk
153, Grodzisk Mazowiecki
147, Katowice
151, Katowice
141, Kielce
150, Krakow
148, Lodz
144, Lublin
152, Poznan
146, Szczecin
140, Warsaw
145, Warsaw
149, Warsaw
187, Alcorcón
181, Barcelona
184, Donostia / San Sebastian
182, Madrid
183, Vigo
185, Zaragoza
201, Biel
205, Geneva
203, Sankt Gallen
202, Tschugg
204, Zurich
223, Liverpool
224, Middlesbrough
UCB Pharma SA
INDUSTRY